医学
造血干细胞移植
内科学
弥漫性大B细胞淋巴瘤
移植
肿瘤科
不利影响
单中心
化疗
淋巴瘤
外科
作者
Wen Qin,Li Gao,Jingkang Xiong,Qiong Li,Sanbin Wang,Ji‐Shi Wang,Fang Liu,Cheng Zhang,Yao Liu,Peiyan Kong,Xiaotong Peng,Jun Rao,Lei Gao,Xi Zhang
标识
DOI:10.1007/s11596-021-2394-2
摘要
The role of autologous hematopoietic stem cell transplantation (auto-HSCT) following high-dose chemotherapy has been validated and accepted as a standard treatment for patients with relapsed diffuse large B-cell lymphoma (DLBCL). However, its clinical efficacy as frontline therapy remains to be elucidated. This study aimed to examine the feasibility of frontline auto-HSCT for newly diagnosed intermediate/high-risk DLBCL patients. We retrospectively reviewed the data of 223 patients treated with frontline auto-HSCT or chemotherapy alone (year 2008-2014) from four hospitals. The median follow-up time was 29.4 months. Between the two treatment arms among the intermediate/high-risk DLBCL patients, the 3-year overall survival (OS) and progression-free survival (PFS) rates of patients given frontline auto-HSCT were 87.6% and 81.9%, respectively, and the chemotherapy-alone group showed 3-year OS and PFS rates of 64.9% and 59.59%, respectively. Compared with the chemotherapy-alone group, the frontline auto-HSCT could eliminate the adverse impact of non-germinal center B-cell (GCB) type. In addition, in the frontline auto-HSCT group, patients who achieved complete response (CR) at auto-HSCT had a longer survival time than those who did not achieve CR. Our results suggested that frontline auto-HSCT could improve the prognosis of intermediate/high-risk DLBCL patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI